Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Every article behind this summary — 1 article from 1 outlet